Suppr超能文献

成人 T 细胞淋巴母细胞淋巴瘤中 microRNA 特征的预后和预测价值。

Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.

出版信息

Leukemia. 2019 Oct;33(10):2454-2465. doi: 10.1038/s41375-019-0466-0. Epub 2019 Apr 5.

Abstract

New prognostic factors are needed to establish indications for haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) for T-cell lymphoblastic lymphoma (T-LBL) patients. We used microarray to compare T-LBL tissue samples (n = 75) and fetal thymus tissues (n = 20), and identified 35 differentially expressed miRNAs. Using 107 subjects as the training group, we developed a five-miRNA-based classifier to predict patient survival with LASSO Cox regression: lower risk was associated with better prognosis (disease-free survival (DFS): hazard ratio (HR) 4.548, 95% CI 2.433-8.499, p < 0.001; overall survival (OS): HR 5.030, 95% CI 2.407-10.513, p < 0.001). This classifier displayed good performance in the internal testing set (n = 106) and the independent external set (n = 304). High risk was associated with more favorable response to HSCT (DFS: HR 1.675, 95% CI 1.127-2.488, p = 0.011; OS: HR 1.602, 95% CI 1.055-2.433, p = 0.027). When combined with ECOG-PS and/or NOTCH1/FBXW7 status, this classifier had even better prognostic performance in patients receiving HSCT (DFS: HR 2.088, 95% CI 1.290-3.379, p = 0.003; OS: HR 1.996, 95% CI 1.203-3.311, p = 0.007). The five-miRNA classifier may be a useful prognostic biomarker for T-LBL adults, and could identify subjects who could benefit from HSCT.

摘要

需要新的预后因素来确定 T 细胞淋巴母细胞淋巴瘤(T-LBL)患者首次完全缓解(CR1)时进行造血干细胞移植(HSCT)的适应证。我们使用微阵列比较了 T-LBL 组织样本(n=75)和胎儿胸腺组织(n=20),并鉴定了 35 个差异表达的 miRNA。使用 107 名患者作为训练组,我们通过 LASSO Cox 回归开发了一个基于 5 个 miRNA 的分类器来预测患者的生存情况:低风险与更好的预后相关(无病生存(DFS):风险比(HR)4.548,95%CI 2.433-8.499,p<0.001;总生存(OS):HR 5.030,95%CI 2.407-10.513,p<0.001)。该分类器在内部测试集(n=106)和独立外部集(n=304)中表现出良好的性能。高风险与 HSCT 更有利的反应相关(DFS:HR 1.675,95%CI 1.127-2.488,p=0.011;OS:HR 1.602,95%CI 1.055-2.433,p=0.027)。当与 ECOG-PS 和/或 NOTCH1/FBXW7 状态结合使用时,该分类器在接受 HSCT 的患者中具有更好的预后性能(DFS:HR 2.088,95%CI 1.290-3.379,p=0.003;OS:HR 1.996,95%CI 1.203-3.311,p=0.007)。五 miRNA 分类器可能是 T-LBL 成人的一种有用的预后生物标志物,可识别可能从 HSCT 中受益的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验